These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22249747)

  • 1. Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2.
    Sakkiah S; Thangapandian S; Lee KW
    J Mol Model; 2012 Jul; 18(7):3267-82. PubMed ID: 22249747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR pharmacophore-based virtual screening for the identification of potential inhibitors of tyrosinase.
    Ghayas S; Ali Masood M; Parveen R; Aquib M; Farooq MA; Banerjee P; Sambhare S; Bavi R
    J Biomol Struct Dyn; 2020 Jul; 38(10):2916-2927. PubMed ID: 31334690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
    Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
    Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.
    Sakkiah S; Lee KW
    Acta Pharmacol Sin; 2012 Jul; 33(7):964-78. PubMed ID: 22684028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
    Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
    Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
    Kumar H; Shah A; Sobhia ME
    J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway.
    Vijjulatha M; Lingala Y; Merugu RT
    J Mol Model; 2014 Jul; 20(7):2348. PubMed ID: 24974084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
    Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY
    Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
    Rampogu S; Baek A; Zeb A; Lee KW
    BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Tang C; Zhu X; Huang D; Zan X; Yang B; Li Y; Du X; Qian H; Huang W
    J Mol Model; 2012 Jun; 18(6):2795-804. PubMed ID: 22120948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay.
    Lee YS; Hodoscek M; Kador PF; Sugiyama K
    Chem Biol Interact; 2003 Feb; 143-144():307-16. PubMed ID: 12604217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new inhibitors of aldose reductase from molecular docking and database screening.
    Rastelli G; Ferrari AM; Costantino L; Gamberini MC
    Bioorg Med Chem; 2002 May; 10(5):1437-50. PubMed ID: 11886806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
    Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y
    J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
    Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
    Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications.
    Vyas B; Choudhary S; Singh PK; Kumar M; Verma H; Singh M; Malik AK; Silakari O
    Bioorg Chem; 2020 Mar; 96():103570. PubMed ID: 31978681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting tyrosinase inhibition by 3D QSAR pharmacophore models and designing potential tyrosinase inhibitors from Traditional Chinese medicine database.
    Gao H
    Phytomedicine; 2018 Jan; 38():145-157. PubMed ID: 29425647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation.
    Bavi R; Kumar R; Rampogu S; Kim Y; Kwon YJ; Park SJ; Lee KW
    J Recept Signal Transduct Res; 2017 Jun; 37(3):224-238. PubMed ID: 27485399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics.
    Larif S; Salem CB; Hmouda H; Bouraoui K
    J Mol Graph Model; 2014 Sep; 53():1-12. PubMed ID: 25064438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.